BioPharm News

Dec 11, 2017
By BioPharm International Editors
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
Dec 08, 2017
By BioPharm International Editors
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
Dec 08, 2017
By BioPharm International Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Dec 07, 2017
An increasing number of warning letters shows that FDA is observing more problems with pharmaceutical contract manufacturing.
Dec 06, 2017
By BioPharm International Editors
The company will expand two of its Ohio facilities, investing approximately $145 million to support manufacturing and warehouse operations.
Dec 06, 2017
By BioPharm International Editors
A survey by LNS Research and sponsored by Honeywell showed that industrial companies are not moving quickly to adopt cyber security; calls on CEOs to take action.
Dec 06, 2017
By BioPharm International Editors
The contract research, development, and manufacturing organization has expanded API aseptic manufacturing capacity at its Valladolid, Spain, facility.
Dec 05, 2017
By BioPharm International Editors
Biopharma majors are among the industry stakeholders who have commented and raised questions about FDA’s recently proposed draft guidance for analytical assessment of similarity in biosimilars.
Dec 05, 2017
By BioPharm International Editors
During the November meeting of the agency’s Pharmacovigilance Risk Assessment Committee, review of Esmya (ulipristal acetate) was announced as well as warnings about prostate cancer treatments.
Dec 05, 2017
By BioPharm International Editors
The agency and the European Commission published updated guidance to answer questions about Brexit.
native1_300x100
lorem ipsum